Getinge in the news

Analysts lifted Getinge's fair value to SEK 251.70, following strong Q2 2026 results with increased profitability and stable guidance.

AMF Tjanstepension reduced its stake in Getinge, causing its voting rights to fall below 5%.

Getinge's stock rose 22% over the last year, driven by strong Q2 2026 financial results, but future profitability hinges on managing tariffs and regulatory pressures.

Pareto Securities downgraded Getinge from Buy to Hold, maintaining a SEK 255.00 target, despite the company's strong Q2 2026 organic sales growth and reaffirmed guidance.

Millennium International Management reduced its short position in Getinge and is no longer a public short seller.

Millennium International Management is no longer a public short seller in Getinge, leaving only one public short seller in the company, though 2.55% of the capital is still shorted.

A subsidiary of Getinge recalled 256 PVC thoracic catheters in the US in August 2026 after a single lot failed bacterial endotoxin tests, raising concerns about quality control and potential financial impacts.

DNB Carnegie increased Getinge's price target to SEK 280 from SEK 265 and reiterated a buy rating.

Aruna Nayak, Managing Director for Getinge's India operations, has led the company to significant growth in the rapidly expanding Indian healthcare market by fostering customer relationships and strategic support.

Aruna Nayak, Managing Director of Getinge India, has overseen significant growth in the company's Indian operations over the past four years, driven by market expansion and strong customer support.

Getinge was downgraded by Pareto due to valuation premium, anticipated lower organic growth, and an already priced-in margin recovery.

Pareto Securities lowered its recommendation for Getinge to hold while Bernstein and SEB Equities raised their target prices for the medical equipment manufacturer; other companies also received updated recommendations and target prices.

Getinge acquired High Purity New England in October 2023 for 120M USD in cash, with potential additional contingent milestones.

The medical technology company strengthened quality systems, improved margins, and increased customer loyalty, while facing challenges in China and supply chain limits.

Getinge, a Swedish medical technology company, has experienced persistent margin pressure due to regulatory scrutiny and product remediation, with recent FDA submission for Cardiosave potentially improving its outlook.

Analysts raised their target prices for Getinge's stock after a strong Q2 2026 report, driven by improved margins and a tariff refund.

Getinge's NAVA technology for neonatal ventilatory support will be featured in a national PTV documentary series, highlighting its personalized patient care.

Getinge AB's total employee count grew by 4.9% from 11,615 in 2023 to 12,183 in 2026.

Getinge received a refund for tariffs previously paid under the IEEPA.

Getinge opened a Digital OR Hub in Hamburg, Germany, to accelerate its intelligent digital operating room ecosystem with new software development and clinical expertise.